Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer

DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following advanced lymphoid malignancies:

  • Multiple myeloma, meeting both of the following criteria:

    • Deletion of chromosome 13
    • Elevated pre-transplant lactic dehydrogenase

  • Chronic lymphocytic leukemia (CLL)

    • Failed ≥ 2 prior conventional chemotherapy regimens, including fludarabine
  • Small lymphocytic lymphoma

  • Follicular non-Hodgkin's lymphoma

    • Received ≥ 3 prior conventional chemotherapy regimens

  • Mantle cell lymphoma

    • Received ≥ 3 prior conventional chemotherapy regimens
• Predicted poor outcome and relapsed disease after undergoing autologous stem cell transplantation ≥ 6 months ago
• Measurable disease, defined as any evidence of disease by scans or blood or urine analysis

• At least 8 x 10^6 autologous CD34-positive cells/kg available for transplantation

  • Stem cell mobilization allowed

• Haploidentical related donor available

  • Sex-mismatched
  • Identical for 1 HLA haplotype AND mismatched for ≥ 1 HLA-A, -B, -C, or DRB1 locus of the unshared haplotype
  • No HLA-identical related or unrelated donor available
• Not eligible for first-line autologous stem cell transplantation on protocol FHCRC-1368.00, FHCRC-1366.00, FHCRC-1461.00, or FHCRC-1595.00
• No bulky disease, defined as total volume of all measurable tumor > 500 cc
• No CNS disease resistant to therapy

PATIENT CHARACTERISTICS:

Age

• 18 to 69

Performance status

• Karnofsky 70-100%

Life expectancy

• Not specified

Hematopoietic

• Not specified

Hepatic

• Liver function tests or liver enzymes ≤ 2 times upper limit of normal

Renal

• Not specified

Cardiovascular

• Ejection fraction ≥ 45%
• No symptomatic cardiac disease

Pulmonary

• DLCO ≥ 50%

Other

• Not pregnant or nursing
• Fertile patients must use effective contraception
• HIV Negative
• No active infection

PRIOR CONCURRENT THERAPY:

Biologic therapy

• See Disease Characteristics
• No prior allogeneic stem cell transplantation

Chemotherapy

• See Disease Characteristics

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified

Other

• No concurrent contrast dye during and for 3 weeks after completion of interleukin-2 administration